It was Christmas come early for publicly funded TB programs and for advocates of improved tuberculosis regimens when the maker of a rifapentine, a drug that can shorten treatment for tuberculosis infection from as much as nine months to three months announced Thursday it will drop its price for the medicine to a dollar a […]
HIV
Dr. Manasseh Phiri was working at the Centre for Infectious Disease Research in Zambia when I met him 10 years ago, although his days as a […]
Tuberculosis
In sub-Saharan Africa where the odds of dying within a year of starting treatment for HIV can still hover close to one-in-10, diagnosing and treating TB […]
Research & Development
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
Policy
The following is a guest post by Heather B. Davis, MPH, and Emily A. Bobrow, PhD, MPH, of MEASURE Evaluation Who has a strategic interest in […]